Replies to post #2678 on Repros Therapeutics, Inc. (RPRX)

[dewophile]

beyond their oral gnrh antagonist, i don't follow the company
i only brought it up because from what i understand much (if not all) of the company's value moving forward will be based on this candidate, so comparing EVs will be interesting once the smoke clears. NBIX may float under cash if they persist in sinking money into indiplon - but if they do the smart thing and just drop it then it'll be interesting to see how the market values the 2 drugs